Adalimumab toolkit for commissioners and providers

The Commissioning Support Units have produced an interactive toolkit and associated resources on behalf of (and approved by) the Regional Medicines Optimisation Committees. These resources are for use by commissioners and providers to support implementation of best-value biologic medicines, with particular focus on adalimumab as biosimilars will become available following the Humira® (biologic originator) patent expiry in October 2018.  The toolkit is also supported by a number of other documents.

On this page you can find:

  • Biosimilar Adalimumab Toolkit (updated October 2018)
  • Best Value Biologic Implementation Plan template (for local adaptation)
  • Template DTC application form for biosimilar adoption
  • Template Terms of Reference for Best Value Biologic Adalimumab Implementation Group
  • Best Value Biologic (including biosimilars) savings calculator & tracker
  • An example home care patient permission letter
  • An example home care risk assessment tool

 

AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources

Attachments